z-logo
open-access-imgOpen Access
First successful case of platinum‐based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations
Author(s) -
Omura Minami,
Kosaka Takeo,
Aimono Eriko,
Nakamura Kohei,
Hongo Hiroshi,
Mikami Shuji,
Nishihara Hiroshi,
Oya Mototsugu
Publication year - 2022
Publication title -
iju case reports
Language(s) - English
Resource type - Journals
ISSN - 2577-171X
DOI - 10.1002/iju5.12383
Subject(s) - pten , prostate cancer , medicine , oncology , chemotherapy , dna damage repair , prostate , cancer , cancer research , bioinformatics , pi3k/akt/mtor pathway , gene , biology , dna repair , apoptosis , genetics
Deoxyribonucleic acid repair gene mutations are now being studied in a variety of solid tumors, with the hope of predicting prognosis, pathogenesis, and treatment outcomes. Case presentation We report the case of a Japanese patient with advanced castration‐resistant prostate cancer who exhibited a prominent response to platinum therapy and had coexisting BRCA2 and PTEN mutations according to retrospective multigene panel analysis. Conclusion Through a review of clinical outcomes and genetic/pathologic profiling, the presented case provides insights into future management strategies based on the tumor genetic status.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here